Imcyse

Imcyse

Imcyse

Developing disease specific immune therapies to treat severe, chronic auto-immune, inflammatory, allergic, infectious diseases and tumors.
Raised
$35M
Latest funding
$35,000,000
Venture capital (Series B) - 2019
LSP BioVentures Epimède SA
Team Size
1–10
Employees
Location
Headquarters
$35,000,000 Venture capital (Series B)
PE HUB

Imcyse raises 35 mln euros